News &amp; Updates

Treatment with anticoagulants helps improve survival in patients with cirrhosis and portal vein thrombosis independently of recanalization, suggests a study. However, anticoagulation may increase the risk of nonportal hypertension-related bleeding.

Anticoagulation lowers mortality in patients with cirrhosis, portal vein thrombosis

‘Triple-G’ obesity drug also targets NAFLD in phase II trial

11 Jul 2023 by

In a subanalysis of a phase II trial on obesity, retatrutide, a triagonist of GIP*, GLP**, and glucagon receptors, also demonstrated multiple favourable signals for nonalcoholic fatty liver disease (NAFLD).

‘Triple-G’ obesity drug also targets NAFLD in phase II trial

11 Jul 2023

Intralesional botulinum toxin proven safe, effective in nail psoriasis

11 Jul 2023 by

A single injection of intralesional botulinum toxin (BTX) demonstrates long-term efficacy and is well tolerated in patients with nail psoriasis, according to a randomized intraindividual controlled study presented at the recent WCD 2023. BTX is also as effective as multiple intralesional steroid injections.

Intralesional botulinum toxin proven safe, effective in nail psoriasis

KEYNOTE-826: Sustained survival benefit with pembro + chemo in advanced cervical cancer

11 Jul 2023 by

The addition of pembrolizumab immunotherapy to chemotherapy, either with or without bevacizumab, continues to confer survival benefit in patients with persistent, recurrent, or metastatic cervical cancer, regardless of their programmed death-ligand 1 (PD-L1) combined positive score (CPS), according to the updated results of the KEYNOTE-826 trial presented at ASCO 2023.

KEYNOTE-826: Sustained survival benefit with pembro + chemo in advanced cervical cancer

Spesolimab curbs flares in generalized pustular psoriasis

The anti-interleukin (IL)-36 receptor monoclonal antibody spesolimab not only helps treat generalized pustular psoriasis (GPP) flares but also prevent them, according to the results of the Effisayil 2 study presented at WCD 2023.

Spesolimab curbs flares in generalized pustular psoriasis

$Tocilizumab an effective substitute to anti-TNF agents in refractory Behçet disease$

Tocilizumab an effective substitute to anti-TNF agents in refractory Behçet disease

Tocilizumab (TCZ) may be used as an alternative treatment to antitumour necrosis factor (anti-TNF) agents for patients with Behçet disease (BD)-related uveitis and neurological manifestations, a recent study has shown.

Tocilizumab an effective substitute to anti-TNF agents in refractory Behçet disease

Does polypharmacy affect survival in older patients with haematological malignancy?

Polypharmacy does not appear to result in poorer treatment response and survival in older patients with different haematological malignancies, as shown in a study presented at the recent EHA 2023.

Does polypharmacy affect survival in older patients with haematological malignancy?

Novel hepcidin mimetic shows remarkable potential for polycythemia vera

In the three-part, phase II REVIVE study, the investigational, first-in-class hepcidin mimetic rusfertide was highly effective in regulating haematocrit levels in individuals with polycythemia vera (PV) who had a high phlebotomy burden.

Novel hepcidin mimetic shows remarkable potential for polycythemia vera

Vorasidenib may be chemo–RT-sparing in certain low-grade gliomas

The oral drug vorasidenib delays disease progression compared with placebo in patients with residual or recurrent grade 2 gliomas harbouring an isocitrate dehydrogenase 1 or 2 (IDH1 or IDH2) mutation in the phase III INDIGO trial.

Vorasidenib may be chemo–RT-sparing in certain low-grade gliomas